G protein-coupled receptor 142Genealiases: GPRg1b · PGR2
Q-omics provides the consensus-scored GPR142 profile across patient tissues and cancer cell-line models. GPR142 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GPR142 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, GPR142 RNA expression shows 13,891 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, THCA, and TGCT as cancer lineages where GPR142 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR142 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR142 survival associations across molecular data types. GPR142 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR142 RNA expression–survival associations across cancer types. High GPR142 expression shows unfavorable associations in UCEC and KIRP, but favorable associations in SKCM, UCS, PAAD and LIHC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for GPR142 RNA expression.
This table summarizes GPR142 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GPR142. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR142 shows lower tumor expression in THCA, COAD, BRCA, UCEC and READ and higher tumor expression in KIRC. The THCA box plot shows higher GPR142 RNA expression in normal versus tumor tissue (log2 FC = −1.264, t-test p < 0.001).
This table shows molecular features associated with GPR142 in patient tissues and cancer cell lines. In patient samples, GPR142 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR142 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
